Literature DB >> 48505

Release of histamine from rat mast cells by the complement peptides C3a and C5a.

A R Johnson, T E Hugli, H J Müller-Eberhard.   

Abstract

Suspensions of rat mast cells were used to study the histamine-releasing actions of anaphylatoxins C3A and C5a in vitro. The peptides, derived from human or porcine complement proteins C3 and C5, were less potent than 48/80 but more potent than bradykinin in stimulating release of histamine from mast cells. The pattern of release resembled that of the anaphylactic release action, e.g. release was limited to less than 30 per cent of the cell histamine, the reaction was calcium-dependent and was potentiated by phosphatidyl serine. When C3a and C5a were added together to mast cell suspensions, the amount of histamine released was additive. Similarly, release by either peptide combined with bradykinin was additive. Histamine-releasing activity (as well as smooth muscle-stimulating activity) was abolished when the peptides were treated with pancreatic carboxy-peptidase B. Active or inactive peptides were bound by mast cells and addition of active C3a in combination with the inactive, des-arginine derivative, C3ai, resulted in partial inhibition of histamine release.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48505      PMCID: PMC1445888     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Comparison of several methods for isolation of rat peritoneal mast cells.

Authors:  A R Johnson; N C Moran
Journal:  Proc Soc Exp Biol Med       Date:  1966-12

2.  Mechanisms of immunologic injury of rat peritoneal mast cells. 3. Cytotoxic histamine release.

Authors:  M D Valentine; K J Bloch; K F Austen
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

3.  Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis.

Authors:  C M Arroyave; H J Müller-Eberhard
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

4.  Release of histamine from rat mast cells: a comparison of the effects of 48-80 and two antigen systems.

Authors:  A R Johnson; N C Moran
Journal:  Fed Proc       Date:  1969 Sep-Oct

5.  A neutrophil chemotactic factor from human C'5.

Authors:  P A Ward; L J Newman
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

6.  A fragment of the third component of human complement with anaphylatoxin activity.

Authors:  D B Budzko; V A Bokisch; H J Müller-Eberhard
Journal:  Biochemistry       Date:  1971-03-30       Impact factor: 3.162

7.  Preparations of purified antigens from Staphylococcus aureus in biologic and serologic experiments. The effects of fractions A-1, A-2, A-3, B and C on dermal reactivity of the rabbit to epinephrine and on isolated ileum from normal guinea-pigs. Occurrence of precipitins in sera from normal rabbits and guinea-pigs.

Authors:  T Löfkvist
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

8.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

9.  Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement.

Authors:  W Dias Da Silva; I H Lepow
Journal:  J Exp Med       Date:  1967-05-01       Impact factor: 14.307

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

View more
  75 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  The effect of soluble material from mouldy hay dust on the complement system.

Authors:  J H Edwards
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

3.  The C5a receptor is expressed by human renal proximal tubular epithelial cells.

Authors:  R Zahedi; M Braun; R A Wetsel; B H Ault; A Khan; T R Welch; M Frenzke; A E Davis
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.

Authors:  Beatrix Schäfer; Adrian M Piliponsky; Tatsuya Oka; Chang Ho Song; Norma P Gerard; Craig Gerard; Mindy Tsai; Janet Kalesnikoff; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2012-06-22       Impact factor: 10.793

Review 5.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Flavoxobin, a serine protease from Trimeresurus flavoviridis (habu snake) venom, independently cleaves Arg726-Ser727 of human C3 and acts as a novel, heterologous C3 convertase.

Authors:  Chieko Yamamoto; Daisuke Tsuru; Naoko Oda-Ueda; Motonori Ohno; Shosaku Hattori; Sung-Teh Kim
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

8.  Anaphylaxis following intranasal challenge of mice sensitized with ovalbumin.

Authors:  A C McCaskill; C S Hosking; D J Hill
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

9.  Antazoline as an adjuvant in immunosuppressive therapy in renal transplant patients.

Authors:  A Montandon; D Brügger; J Hodler
Journal:  Klin Wochenschr       Date:  1986-06-16

10.  C4a: the third anaphylatoxin of the human complement system.

Authors:  J P Gorski; T E Hugli; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.